Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants

PURPOSE: Biological therapies targeting eosinophils have been shown to be effective in treating patients with severe eosinophilic asthma. Benralizumab (Fasenra(®), AstraZeneca) is a humanized monoclonal antibody binding to the alpha subunit of the interleukin-5 receptor, which rapidly depletes eosin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Tommy Tsang, Mai, Tu H, Chia, Yen Lin, Yap, Desmond Y H, Lee, Chi-Ho, Chen, Cecil Chi-Keung, Huang, Ying, Jin, Yuwen, Johnston, James, Werkström, Viktoria, Yao, Yuhui, Ge, Xiaoyun, Zheng, Wenying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885872/
https://www.ncbi.nlm.nih.gov/pubmed/36726737
http://dx.doi.org/10.2147/DDDT.S392155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885872/
https://www.ncbi.nlm.nih.gov/pubmed/36726737
http://dx.doi.org/10.2147/DDDT.S392155

Ejemplares similares